4-氨基-4-哌啶腈 | 50289-05-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 4-氨基-4-哌啶腈
• 英文名称: 4-Amino-4-piperidinecarbonitrile
• 英文别名: 4-aminopiperidine-4-carbonitrile
• CAS: 50289-05-9
• 化学式: C₆H₁₁N₃
• 分子量: 125.17
• InChiKey: YRQZAUSIVGMFNN-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• 4,4-DISUBSTITUTED PIPERIDINE DERIVATIVES
  申请人：Christ Andreas D.

  公开号：US20080293756A1

  公开（公告）日：2008-11-27

  This invention relates to 4,4-disubstituted piperidine derivatives of the formula wherein A and R 1 to R 5 are as defined in the specification, and pharmaceutically acceptable salts thereof. The invention further relates to pharmaceutical compositions containing such compounds, to a process for their preparation and to their use for the treatment and/or prevention of diseases which are associated with the modulation of SST receptors subtype 5.

  这项发明涉及公式 的4,4-二取代哌啶衍生物，其中A和R1至R5如规范中所定义，并其药学上可接受的盐。该发明还涉及含有这种化合物的药物组合物，以及用于制备它们的方法和它们用于治疗和/或预防与调节SST受体亚型5相关的疾病的用途。
• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc

  公开号：US20040248881A1

  公开（公告）日：2004-12-09

  Compounds of Formula (I) or (II) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  化合物的化学式（I）或（II），其作为大麻素受体配体并在治疗与动物体内大麻素受体介导相关疾病中的用途被描述在此。
• [EN] PURINE COMPOUNDS AND USES THEREOF AS CANNABINOID RECEPTOR LIGANDS<br/>[FR] COMPOSES PURINIQUES ET LEURS UTILISATIONS COMME LIGANDS DE RECEPTEURS DES CANNABINOIDES
  申请人：PFIZER PROD INC

  公开号：WO2004037823A1

  公开（公告）日：2004-05-06

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• [EN] IMIDAZOLE COMPOUNDS AND USES THEREOF<br/>[FR] COMPOSES D'IMIDAZOLE ET LEURS UTILISATIONS
  申请人：PFIZER PROD INC

  公开号：WO2005009974A1

  公开（公告）日：2005-02-03

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the activation of the cannabinoid receptors in animals are described herein.

  本文描述了作为大麻素受体配体的化合物(I)及其在治疗与动物大麻素受体激活相关的疾病中的用途。
• Novel compounds useful as reversible inhibitors of cysteine proteases
  申请人：——

  公开号：US20020137932A1

  公开（公告）日：2002-09-26

  Disclosed are novel cathepsin S, K, F, L and B reversible inhibitory compounds of the formula (Ia) and (Ib) where R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 , Het and X are defined herein. The compounds are useful for treating autoimmune and other diseases. Also disclosed are processes for making such novel compounds. 1

  揭示了一种新型的cathepsin S、K、F、L和B的可逆抑制化合物，其化学式为(Ia)和(Ib)，其中R2、R3、R4、R5、R6、R7、R8、Het和X的定义如下。这些化合物可用于治疗自身免疫和其他疾病。还公开了制备这种新型化合物的方法。